HDAC1 and familial pancreatic carcinoma: KRAS and HDAC1 gene mutations may be early events in the molecular pathogenic cascade that leads to PDAC and thus they are potential targets for pancreatic cancer gene therapy.[99, 100] A study used multi‐functionalized monolayer graphene oxide (GO) as a gene delivery vehicle to effectively co‐deliver HDAC1 and K‐Ras siRNAs (small interfering RNAs) targeting the HDAC1 gene and the mutant K‐Ras gene in pancreatic cancer cells MIA PaCa‐2.